Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | MPL | P40238 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FZD7 | O75084 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455606 | 0.87 | TAS1R3 (0.40) | EPHX2KDM4EMAPTKMT2AALDH1A1 | |
| SCHEMBL1455074 | 0.82 | EPHX2 (0.39) | EPHX2GCKKDM4EMAPTKMT2A | |
| SCHEMBL1454596 | 0.81 | EPHX2 (0.50) | EPHX2KDM4EMAPTKMT2AALDH1A1 | |
| SCHEMBL4975269 | 0.81 | GCK (0.47) | GCKGRM5MPLKDM4EMAPT | |
| SCHEMBL1455931 | 0.80 | EPHX2 (0.42) | EPHX2KDM4EMAPTKMT2AABL1 | |
| SCHEMBL1454290 | 0.80 | EPHX2 (0.41) | EPHX2KDM4EMAPTKMT2AABL1 | |
| SCHEMBL1454647 | 0.80 | ABL1 (0.35) | MPLABL1KIT | |
| SCHEMBL1455067 | 0.79 | EPHX2 (0.42) | EPHX2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1455409 | 0.78 | NPC1 (0.42) | EPHX2KDM4EMAPTPOLBKMT2A | |
| SCHEMBL1455410 | 0.78 | F10 (0.42) | EPHX2KDM4EMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | EPHX2 3223/4885GCK 1165/4885GRM5 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.